Seeking Alpha

Vertex Pharmaceuticals (VRTX +0.1%) bucks a weak tape this morning after saying it's entered...

Vertex Pharmaceuticals (VRTX +0.1%) bucks a weak tape this morning after saying it's entered into a non-exclusive agreement with Bristol-Myers Squibb (BMY -0.3%) to conduct Phase 2 studies of VRTX's VX-135 in combination with BMY's daclatasvir for the treatment of hepatitis C. As part of the agreement, VRTX will also conduct two Phase 2 studies of the combination, including an initial study in treatment-naive people with genotype 1 HCV infection. The second study is planned for Q2.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)